{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:51:03Z","timestamp":1791827463927,"version":"4.3.4"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"DOI":"10.1007\/s00011-026-02390-8","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:27:20Z","timestamp":1791826040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inflammatory bowel disease and breast cancer: epidemiological evidence, shared biology, and clinical management"],"prefix":"10.1007","volume":"75","author":[{"given":"Qianqian","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8962-3869","authenticated-orcid":false,"given":"Sijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"3","key":"2390_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"10114","key":"2390_CR2","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/s0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769\u201378. https:\/\/doi.org\/10.1016\/s0140-6736(17)32448-0.","journal-title":"Lancet"},{"issue":"1","key":"2390_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s2468-1253(19)30333-4","volume":"5","author":"S Alatab","year":"2020","unstructured":"Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17\u201330. https:\/\/doi.org\/10.1016\/s2468-1253(19)30333-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2390_CR4","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","volume":"17","author":"H Gordon","year":"2023","unstructured":"Gordon H, Biancone L, Fiorino G, Katsanos KH, Kopylov U, Al Sulais E, et al. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis. 2023;17:827\u201354. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac187.","journal-title":"J Crohns Colitis"},{"issue":"7","key":"2390_CR5","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.cgh.2024.03.032","volume":"22","author":"JE Axelrad","year":"2024","unstructured":"Axelrad JE, Hashash JG, Itzkowitz SH. AGA clinical practice update on management of inflammatory bowel disease in patients with malignancy: commentary. Clin Gastroenterol Hepatol. 2024;22(7):1365\u201372. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.032.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2390_CR6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.cgh.2019.06.042","volume":"18","author":"JE Axelrad","year":"2020","unstructured":"Axelrad JE, Bazarbashi A, Zhou J, Casta\u00f1eda D, Gujral A, Sperling D, et al. Hormone therapy for cancer is a risk factor for relapse of inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020;18(4):872\u2013e801. https:\/\/doi.org\/10.1016\/j.cgh.2019.06.042.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2390_CR7","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1245\/s10434-014-4198-0","volume":"22","author":"MS Tsai","year":"2015","unstructured":"Tsai MS, Chen HP, Hung CM, Lee PH, Lin CL, Kao CH. Hospitalization for inflammatory bowel disease is associated with increased risk of breast cancer: a nationwide cohort study of an asian population. Ann Surg Oncol. 2015;22(6):1996\u20132002. https:\/\/doi.org\/10.1245\/s10434-014-4198-0.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2390_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.cgh.2013.03.034","volume":"12","author":"MD Kappelman","year":"2014","unstructured":"Kappelman MD, Farkas DK, Long MD, Erichsen R, Sandler RS, S\u00f8rensen HT, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12(2):265\u2013e731. https:\/\/doi.org\/10.1016\/j.cgh.2013.03.034.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2390_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/cej.0000000000000667","volume":"31","author":"C Gong","year":"2022","unstructured":"Gong C, Xu R, Zou P, Zhang Y, Wang X. Inflammatory bowel disease and risk of breast cancer: a meta-analysis of cohort studies. Eur J Cancer Prev. 2022;31:54\u201363. https:\/\/doi.org\/10.1097\/cej.0000000000000667.","journal-title":"Eur J Cancer Prev"},{"key":"2390_CR10","doi-asserted-by":"publisher","first-page":"1392341","DOI":"10.3389\/fgene.2024.1392341","volume":"15","author":"Y Yin","year":"2024","unstructured":"Yin Y, Zhang X. The causal association between inflammatory bowel disease and breast cancer: a bidirectional two-sample Mendelian randomization study. Front Genet. 2024;15:1392341. https:\/\/doi.org\/10.3389\/fgene.2024.1392341.","journal-title":"Front Genet"},{"key":"2390_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12916-023-03096-y","volume":"21","author":"H Gao","year":"2023","unstructured":"Gao H, Zheng S, Yuan X, Xie J, Xu L. Causal association between inflammatory bowel disease and 32 site-specific extracolonic cancers: a Mendelian randomization study. BMC Med. 2023;21:389. https:\/\/doi.org\/10.1186\/s12916-023-03096-y.","journal-title":"BMC Med"},{"key":"2390_CR12","doi-asserted-by":"publisher","first-page":"e38392","DOI":"10.1097\/md.0000000000038392","volume":"103","author":"Z Guo","year":"2024","unstructured":"Guo Z, Xu C, Fang Z, Yu X, Yang K, Liu C, et al. Inflammatory bowel disease and breast cancer: a two-sample bidirectional Mendelian randomization study. Med (Baltim). 2024;103:e38392. https:\/\/doi.org\/10.1097\/md.0000000000038392.","journal-title":"Med (Baltim)"},{"issue":"1","key":"2390_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12916-024-03352-9","volume":"22","author":"D Liu","year":"2024","unstructured":"Liu D, Cao M, Wang H, Cao W, Zheng C, Li Y, et al. Association between inflammatory bowel disease and cancer risk: evidence triangulation from genetic correlation, Mendelian randomization, and colocalization analyses across East Asian and European populations. BMC Med. 2024;22(1):137. https:\/\/doi.org\/10.1186\/s12916-024-03352-9.","journal-title":"BMC Med"},{"key":"2390_CR14","doi-asserted-by":"publisher","first-page":"1591745","DOI":"10.3389\/fmicb.2025.1591745","volume":"16","author":"X Ren","year":"2025","unstructured":"Ren X, Zheng L, Huang L, Zhao J. The role of the gut microbiota in shaping the tumor microenvironment and immunotherapy of breast cancer. Front Microbiol. 2025;16:1591745. https:\/\/doi.org\/10.3389\/fmicb.2025.1591745.","journal-title":"Front Microbiol"},{"issue":"11","key":"2390_CR15","doi-asserted-by":"publisher","first-page":"e1847","DOI":"10.1002\/cnr2.1847","volume":"6","author":"SS Chapadgaonkar","year":"2023","unstructured":"Chapadgaonkar SS, Bajpai SS, Godbole MS. Gut microbiome influences incidence and outcomes of breast cancer by regulating levels and activity of steroid hormones in women. Cancer Rep (Hoboken). 2023;6(11):e1847. https:\/\/doi.org\/10.1002\/cnr2.1847.","journal-title":"Cancer Rep (Hoboken)"},{"issue":"9","key":"2390_CR16","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3390\/pathogens12091086","volume":"12","author":"ML Fern\u00e1ndez-Murga","year":"2023","unstructured":"Fern\u00e1ndez-Murga ML, Gil-Ortiz F, Serrano-Garc\u00eda L, Llombart-Cussac A. A new paradigm in the relationship between gut microbiota and breast cancer: \u03b2-glucuronidase enzyme identified as potential therapeutic target. Pathogens. 2023;12(9):1086. https:\/\/doi.org\/10.3390\/pathogens12091086.","journal-title":"Pathogens"},{"issue":"4","key":"2390_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ijc.35427","volume":"157","author":"AH Larnder","year":"2025","unstructured":"Larnder AH, Manges AR, Murphy RA. The estrobolome: Estrogen-metabolizing pathways of the gut microbiome and their relation to breast cancer. Int J Cancer. 2025;157(4):599\u2013613. https:\/\/doi.org\/10.1002\/ijc.35427.","journal-title":"Int J Cancer"},{"issue":"2","key":"2390_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s12282-024-01658-3","volume":"32","author":"G Gamba","year":"2025","unstructured":"Gamba G, Colonetti T, Uggioni MLR, Elibio LU, Balbinot EL, Heinzen R, et al. Gut microbiota and breast cancer: systematic review and meta-analysis. Breast Cancer. 2025;32(2):242\u201357. https:\/\/doi.org\/10.1007\/s12282-024-01658-3.","journal-title":"Breast Cancer"},{"issue":"1","key":"2390_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12088-023-01135-z","volume":"64","author":"NE Mahno","year":"2024","unstructured":"Mahno NE, Tay DD, Khalid NS, Yassim ASM, Alias NS, Termizi SA, et al. The relationship between gut microbiome estrobolome and breast cancer: a systematic review of current evidences. Indian J Microbiol. 2024;64(1):1\u201319. https:\/\/doi.org\/10.1007\/s12088-023-01135-z.","journal-title":"Indian J Microbiol"},{"issue":"1","key":"2390_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12929-018-0483-8","volume":"25","author":"LC-H Yu","year":"2018","unstructured":"Yu LC-H. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. J Biomed Sci. 2018;25(1):79. https:\/\/doi.org\/10.1186\/s12929-018-0483-8.","journal-title":"J Biomed Sci"},{"issue":"12","key":"2390_CR21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3390\/metabo14120683","volume":"14","author":"R Mir","year":"2024","unstructured":"Mir R, Albarqi SA, Albalawi W, Alatwi HE, Alatawy M, Bedaiwi RI, et al. Emerging role of gut microbiota in breast cancer development and its implications in treatment. Metabolites. 2024;14(12):683. https:\/\/doi.org\/10.3390\/metabo14120683.","journal-title":"Metabolites"},{"issue":"4","key":"2390_CR22","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41423-021-00661-4","volume":"18","author":"W Yang","year":"2021","unstructured":"Yang W, Cong Y. Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases. Cell Mol Immunol. 2021;18(4):866\u201377. https:\/\/doi.org\/10.1038\/s41423-021-00661-4.","journal-title":"Cell Mol Immunol"},{"issue":"7","key":"2390_CR23","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/cancers17071102","volume":"17","author":"E Carvalho","year":"2025","unstructured":"Carvalho E, Canberk S, Schmitt F, Vale N. Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies. Cancers (Basel). 2025;17(7):1102. https:\/\/doi.org\/10.3390\/cancers17071102.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2390_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41523-021-00332-7","volume":"7","author":"H Vos","year":"2021","unstructured":"Vos H, Lambein K, Richard F, Mari\u00ebn B, Nevelsteen I, Punie K, et al. Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer. npj Breast Cancer. 2021;7(1):128. https:\/\/doi.org\/10.1038\/s41523-021-00332-7.","journal-title":"npj Breast Cancer"},{"issue":"1","key":"2390_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","volume":"94","author":"GP Ramos","year":"2019","unstructured":"Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. Mayo Clin Proc. 2019;94(1):155\u201365. https:\/\/doi.org\/10.1016\/j.mayocp.2018.09.013.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"2390_CR26","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/ijms24021526","volume":"24","author":"A Saez","year":"2023","unstructured":"Saez A, Herrero-Fernandez B, Gomez-Bris R, S\u00e1nchez-Martinez H, Gonzalez-Granado JM. Pathophysiology of inflammatory bowel disease: innate immune system. Int J Mol Sci. 2023;24(2):1526. https:\/\/doi.org\/10.3390\/ijms24021526.","journal-title":"Int J Mol Sci"},{"key":"2390_CR27","doi-asserted-by":"publisher","first-page":"1393463","DOI":"10.3389\/fimmu.2024.1393463","volume":"15","author":"Z Tian","year":"2024","unstructured":"Tian Z, Zhao Q, Teng X. Anti-IL23\/12 agents and JAK inhibitors for inflammatory bowel disease. Front Immunol. 2024;15:1393463. https:\/\/doi.org\/10.3389\/fimmu.2024.1393463.","journal-title":"Front Immunol"},{"issue":"8","key":"2390_CR28","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andr\u00e9 F, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)\u2020. Ann Oncol. 2018;29(8):1634\u201357. https:\/\/doi.org\/10.1093\/annonc\/mdy192.","journal-title":"Ann Oncol"},{"issue":"9","key":"2390_CR29","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3390\/ph16091272","volume":"16","author":"M Imbrizi","year":"2023","unstructured":"Imbrizi M, Magro F, Coy CSR. Pharmacological therapy in inflammatory bowel diseases: a narrative review of the past 90 years. Pharmaceuticals (Basel). 2023;16(9):1272. https:\/\/doi.org\/10.3390\/ph16091272.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"Suppl 1","key":"2390_CR30","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1093\/ibd\/zaa010.056","volume":"26","author":"E Mansoor","year":"2020","unstructured":"Mansoor E, Abou-Saleh M, Sarmini MT, Chouhan V, Regueiro M, Katz J, et al. P126 Epidemiology and risk factors of breast cancer in inflammatory bowel disease in the United States between 2014 and 2019: a population-based study. Inflamm Bowel Dis. 2020;26(Suppl 1):S24\u20135. https:\/\/doi.org\/10.1093\/ibd\/zaa010.056.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"2390_CR31","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.cgh.2024.09.034","volume":"23","author":"G Le Cosquer","year":"2025","unstructured":"Le Cosquer G, Kirchgesner J, Gilletta De Saint Joseph C, Seksik P, Amiot A, Laharie D, et al. Risk of incident cancer in patients with inflammatory bowel disease with prior breast cancer: a multicenter cohort study. Clin Gastroenterol Hepatol. 2025;23(10):1824\u2013e333. https:\/\/doi.org\/10.1016\/j.cgh.2024.09.034.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"2390_CR32","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1002\/art.39738","volume":"68","author":"R Mamtani","year":"2016","unstructured":"Mamtani R, Clark AS, Scott FI, Brensinger CM, Boursi B, Chen L, et al. Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study. Arthritis Rheumatol. 2016;68(10):2403\u201311. https:\/\/doi.org\/10.1002\/art.39738.","journal-title":"Arthritis Rheumatol"},{"key":"2390_CR33","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/ibd\/izac035","volume":"28","author":"SJ Hong","year":"2022","unstructured":"Hong SJ, Zenger C, Pecoriello J, Pang A, Vallely M, Hudesman DP, et al. Ustekinumab and vedolizumab are not associated with subsequent cancer in IBD patients with prior malignancy. Inflamm Bowel Dis. 2022;28:1826\u201332. https:\/\/doi.org\/10.1093\/ibd\/izac035.","journal-title":"Inflamm Bowel Dis"},{"key":"2390_CR34","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1007\/s12672-025-04173-9","volume":"16","author":"L Zeng","year":"2025","unstructured":"Zeng L, Zhang J, Liu X, Yang X, Nie Q. Genetic and immune regulatory links between inflammatory bowel disease and breast cancer involving the JAK STAT PD L1 axis. Discov Oncol. 2025;16:2332. https:\/\/doi.org\/10.1007\/s12672-025-04173-9.","journal-title":"Discov Oncol"},{"key":"2390_CR35","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2147\/bctt.s546371","volume":"17","author":"D Zhang","year":"2025","unstructured":"Zhang D, Guan Y, Tang H, Xue Q, Li X, Bin X, et al. Common biomarkers and pathogenesis of inflammatory bowel disease and breast cancer: mendelian randomization and multi-omics studies. Breast Cancer (Dove Med Press). 2025;17:1183\u201397. https:\/\/doi.org\/10.2147\/bctt.s546371.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"4","key":"2390_CR36","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1017\/s1460396920000783","volume":"20","author":"JN Cantrell","year":"2021","unstructured":"Cantrell JN, Vidal GS, Bitar H, Ahmad S, Gunter TC. Should inflammatory bowel disease be a contraindication to radiation therapy: a systematic review of acute and late toxicities. J Radiother Pract. 2021;20(4):480\u20139. https:\/\/doi.org\/10.1017\/s1460396920000783.","journal-title":"J Radiother Pract"},{"key":"2390_CR37","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1200\/jco.19.01674","volume":"38","author":"H Abu-Sbeih","year":"2020","unstructured":"Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, et al. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol. 2020;38:576\u201383. https:\/\/doi.org\/10.1200\/jco.19.01674.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2390_CR38","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/apt.16217","volume":"53","author":"J Meserve","year":"2021","unstructured":"Meserve J, Facciorusso A, Holmer AK, Annese V, Sandborn WJ, Singh S. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Aliment Pharmacol Ther. 2021;53(3):374\u201382. https:\/\/doi.org\/10.1111\/apt.16217.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2390_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ccr.2012.11.013","volume":"23","author":"J Liang","year":"2013","unstructured":"Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013;23(1):107\u201320. https:\/\/doi.org\/10.1016\/j.ccr.2012.11.013.","journal-title":"Cancer Cell"},{"key":"2390_CR40","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1158\/0008-5472.can-11-3917","volume":"72","author":"M Velasco-Velazquez","year":"2012","unstructured":"Velasco-Velazquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012;72:3839\u201350. https:\/\/doi.org\/10.1158\/0008-5472.can-11-3917.","journal-title":"Cancer Res"},{"issue":"5","key":"2390_CR41","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nm.4307","volume":"23","author":"NR West","year":"2017","unstructured":"West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23(5):579\u201389. https:\/\/doi.org\/10.1038\/nm.4307.","journal-title":"Nat Med"},{"issue":"1","key":"2390_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/vaccines4010005","volume":"4","author":"S Zundler","year":"2016","unstructured":"Zundler S, Neurath MF. Integrating immunologic signaling networks: The JAK\/STAT pathway in colitis and colitis-associated cancer. Vaccines (Basel). 2016;4(1):5. https:\/\/doi.org\/10.3390\/vaccines4010005.","journal-title":"Vaccines (Basel)"},{"issue":"28","key":"2390_CR43","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.3748\/wjg.v26.i28.4055","volume":"26","author":"F Cordes","year":"2020","unstructured":"Cordes F, Foell D, Ding JN, Varga G, Bettenworth D. Differential regulation of JAK\/STAT-signaling in patients with ulcerative colitis and Crohn\u2019s disease. World J Gastroenterol. 2020;26(28):4055\u201375. https:\/\/doi.org\/10.3748\/wjg.v26.i28.4055.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"2390_CR44","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1172\/jci44745","volume":"121","author":"LL Marotta","year":"2011","unstructured":"Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, et al. The JAK2\/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011;121(7):2723\u201335. https:\/\/doi.org\/10.1172\/jci44745.","journal-title":"J Clin Invest"},{"issue":"6","key":"2390_CR45","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189\u2013201. https:\/\/doi.org\/10.1016\/j.celrep.2017.04.031.","journal-title":"Cell Rep"},{"issue":"1","key":"2390_CR46","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41598-023-27887-8","volume":"13","author":"AS Roesler","year":"2023","unstructured":"Roesler AS, Malasi S, Koslosky L, Hartmayer P, Naab TJ, Carter JM, et al. PDJ amplicon in triple negative breast cancer. Sci Rep. 2023;13(1):618. https:\/\/doi.org\/10.1038\/s41598-023-27887-8.","journal-title":"Sci Rep"},{"issue":"5","key":"2390_CR47","doi-asserted-by":"publisher","first-page":"e1205","DOI":"10.1016\/j.clbc.2018.05.006","volume":"18","author":"M Chen","year":"2018","unstructured":"Chen M, Pockaj B, Andreozzi M, Barrett MT, Krishna S, Eaton S, et al. JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple-negative breast cancer. Clin Breast Cancer. 2018;18(5):e1205\u201315. https:\/\/doi.org\/10.1016\/j.clbc.2018.05.006.","journal-title":"Clin Breast Cancer"},{"issue":"28","key":"2390_CR48","doi-asserted-by":"publisher","first-page":"26483","DOI":"10.18632\/oncotarget.4494","volume":"6","author":"MT Barrett","year":"2015","unstructured":"Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, et al. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget. 2015;6(28):26483\u201393. https:\/\/doi.org\/10.18632\/oncotarget.4494.","journal-title":"Oncotarget"},{"key":"2390_CR49","doi-asserted-by":"publisher","first-page":"334ra53","DOI":"10.1126\/scitranslmed.aad3001","volume":"8","author":"JM Balko","year":"2016","unstructured":"Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Davila-Gonzalez D, et al. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Sci Transl Med. 2016;8:334ra53. https:\/\/doi.org\/10.1126\/scitranslmed.aad3001.","journal-title":"Sci Transl Med"},{"issue":"9","key":"2390_CR50","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/nejmoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/nejmoa1910549.","journal-title":"N Engl J Med"},{"key":"2390_CR51","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12935-019-1014-8","volume":"19","author":"P Wang","year":"2019","unstructured":"Wang P, Yuan Y, Lin W, Zhong H, Xu K, Qi X. Roles of sphingosine-1-phosphate signaling in cancer. Cancer Cell Int. 2019;19:295. https:\/\/doi.org\/10.1186\/s12935-019-1014-8.","journal-title":"Cancer Cell Int"},{"key":"2390_CR52","doi-asserted-by":"publisher","first-page":"8606878","DOI":"10.1155\/2016\/8606878","volume":"2016","author":"M Aoki","year":"2016","unstructured":"Aoki M, Aoki H, Ramanathan R, Hait NC, Takabe K. Sphingosine-1-phosphate signaling in immune cells and inflammation: roles and therapeutic potential. Mediators Inflamm. 2016;2016:8606878. https:\/\/doi.org\/10.1155\/2016\/8606878.","journal-title":"Mediators Inflamm"},{"issue":"1","key":"2390_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12935-024-03221-8","volume":"24","author":"SS Alkafaas","year":"2024","unstructured":"Alkafaas SS, Elsalahaty MI, Ismail DF, Radwan MA, Elkafas SS, Loutfy SA, et al. The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target. Cancer Cell Int. 2024;24(1):89. https:\/\/doi.org\/10.1186\/s12935-024-03221-8.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"2390_CR54","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.molmed.2017.02.002","volume":"23","author":"OH Nielsen","year":"2017","unstructured":"Nielsen OH, Li Y, Johansson-Lindbom B, Coskun M. Sphingosine-1-phosphate signaling in inflammatory bowel disease. Trends Mol Med. 2017;23(4):362\u201374. https:\/\/doi.org\/10.1016\/j.molmed.2017.02.002.","journal-title":"Trends Mol Med"},{"key":"2390_CR55","doi-asserted-by":"publisher","first-page":"1235656","DOI":"10.3389\/fphys.2023.1235656","volume":"14","author":"F Zou","year":"2023","unstructured":"Zou F, Wang S, Xu M, Wu Z, Deng F. The role of sphingosine-1-phosphate in the gut mucosal microenvironment and inflammatory bowel diseases. Front Physiol. 2023;14:1235656. https:\/\/doi.org\/10.3389\/fphys.2023.1235656.","journal-title":"Front Physiol"},{"key":"2390_CR56","doi-asserted-by":"publisher","first-page":"e24150","DOI":"10.4161\/jkst.24150","volume":"2","author":"AL Theiss","year":"2013","unstructured":"Theiss AL. Sphingosine-1-phosphate: Driver of NFkappaB and STAT3 persistent activation in chronic intestinal inflammation and colitis-associated cancer. JAKSTAT. 2013;2:e24150. https:\/\/doi.org\/10.4161\/jkst.24150.","journal-title":"JAKSTAT"},{"issue":"5","key":"2390_CR57","first-page":"265","volume":"18","author":"T Choden","year":"2022","unstructured":"Choden T, Cohen NA, Rubin DT. Sphingosine-1 phosphate receptor modulators: the next wave of oral therapies in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2022;18(5):265\u201371.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2390_CR58","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jbior.2017.10.005","volume":"67","author":"K Geffken","year":"2018","unstructured":"Geffken K, Spiegel S. Sphingosine kinase 1 in breast cancer. Adv Biol Regul. 2018;67:59\u201365. https:\/\/doi.org\/10.1016\/j.jbior.2017.10.005.","journal-title":"Adv Biol Regul"},{"key":"2390_CR59","doi-asserted-by":"publisher","first-page":"748470","DOI":"10.3389\/fmolb.2021.748470","volume":"8","author":"L-W Hii","year":"2021","unstructured":"Hii L-W, Chung FF-L, Mai C-W, Ng PY, Leong C-O. Sphingosine kinase 1 signaling in breast cancer: a potential target to tackle breast cancer stem cells. Front Mol Biosci. 2021;8:748470. https:\/\/doi.org\/10.3389\/fmolb.2021.748470.","journal-title":"Front Mol Biosci"},{"key":"2390_CR60","doi-asserted-by":"publisher","first-page":"512103","DOI":"10.1155\/2013\/512103","volume":"2013","author":"CD Richards","year":"2013","unstructured":"Richards CD. The enigmatic cytokine oncostatin m and roles in disease. ISRN Inflamm. 2013;2013:512103. https:\/\/doi.org\/10.1155\/2013\/512103.","journal-title":"ISRN Inflamm"},{"key":"2390_CR61","doi-asserted-by":"publisher","first-page":"1239732","DOI":"10.3389\/fimmu.2023.1239732","volume":"14","author":"CL Wolf","year":"2023","unstructured":"Wolf CL, Pruett C, Lighter D, Jorcyk CL. The clinical relevance of OSM in inflammatory diseases: a comprehensive review. Front Immunol. 2023;14:1239732. https:\/\/doi.org\/10.3389\/fimmu.2023.1239732.","journal-title":"Front Immunol"},{"issue":"1","key":"2390_CR62","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4240\/wjgs.v16.i1.228","volume":"16","author":"Y Yang","year":"2024","unstructured":"Yang Y, Fu KZ, Pan G. Role of Oncostatin M in the prognosis of inflammatory bowel disease: a meta-analysis. World J Gastrointest Surg. 2024;16(1):228\u201338. https:\/\/doi.org\/10.4240\/wjgs.v16.i1.228.","journal-title":"World J Gastrointest Surg"},{"issue":"4","key":"2390_CR63","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/biomedicines7040095","volume":"7","author":"CD Richards","year":"2019","unstructured":"Richards CD, Botelho F. Oncostatin M in the regulation of connective tissue cells and macrophages in pulmonary disease. Biomedicines. 2019;7(4):95. https:\/\/doi.org\/10.3390\/biomedicines7040095.","journal-title":"Biomedicines"},{"issue":"7","key":"2390_CR64","doi-asserted-by":"publisher","first-page":"e148667","DOI":"10.1172\/jci148667","volume":"132","author":"AM Araujo","year":"2022","unstructured":"Araujo AM, Abaurrea A, Azcoaga P, Lopez-Velazco JI, Manzano S, Rodriguez J, et al. Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment. J Clin Invest. 2022;132(7):e148667. https:\/\/doi.org\/10.1172\/jci148667.","journal-title":"J Clin Invest"},{"issue":"9","key":"2390_CR65","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1158\/1541-7786.mcr-22-0715","volume":"21","author":"KL Polak","year":"2023","unstructured":"Polak KL, Tamagno I, Parameswaran N, Smigiel J, Chan ER, Yuan X, et al. Oncostatin-M and OSM-receptor feed-forward activation of MAPK induces separable stem-like and mesenchymal programs. Mol Cancer Res. 2023;21(9):975\u201390. https:\/\/doi.org\/10.1158\/1541-7786.mcr-22-0715.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2390_CR66","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13058-018-0971-5","volume":"20","author":"K Tawara","year":"2018","unstructured":"Tawara K, Bolin C, Koncinsky J, Kadaba S, Covert H, Sutherland C, et al. OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung. Breast Cancer Res. 2018;20(1):53. https:\/\/doi.org\/10.1186\/s13058-018-0971-5.","journal-title":"Breast Cancer Res"},{"issue":"21","key":"2390_CR67","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.18632\/oncotarget.26699","volume":"10","author":"K Tawara","year":"2019","unstructured":"Tawara K, Scott H, Emathinger J, Wolf C, LaJoie D, Hedeen D, et al. HIGH expression of OSM and IL-6 are associated with decreased breast cancer survival: synergistic induction of IL-6 secretion by OSM and IL-1\u03b2. Oncotarget. 2019;10(21):2068\u201385. https:\/\/doi.org\/10.18632\/oncotarget.26699.","journal-title":"Oncotarget"},{"issue":"1","key":"2390_CR68","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1038\/s41467-021-24438-5","volume":"12","author":"H Zhang","year":"2021","unstructured":"Zhang H, Chen K, Tan Q, Shao Q, Han S, Zhang C, et al. Structural basis for chemokine recognition and receptor activation of chemokine receptor CCR5. Nat Commun. 2021;12(1):4151. https:\/\/doi.org\/10.1038\/s41467-021-24438-5.","journal-title":"Nat Commun"},{"issue":"1","key":"2390_CR69","doi-asserted-by":"publisher","first-page":"552","DOI":"10.4049\/jimmunol.166.1.552","volume":"166","author":"MN Ajuebor","year":"2001","unstructured":"Ajuebor MN, Hogaboam CM, Kunkel SL, Proudfoot AE, Wallace JL. The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J Immunol. 2001;166(1):552\u20138. https:\/\/doi.org\/10.4049\/jimmunol.166.1.552.","journal-title":"J Immunol"},{"issue":"1","key":"2390_CR70","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.gendis.2021.08.004","volume":"9","author":"Z Zeng","year":"2022","unstructured":"Zeng Z, Lan T, Wei Y, Wei X. CCL5\/CCR5 axis in human diseases and related treatments. Genes Dis. 2022;9(1):12\u201327. https:\/\/doi.org\/10.1016\/j.gendis.2021.08.004.","journal-title":"Genes Dis"},{"issue":"1","key":"2390_CR71","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/path.1245","volume":"199","author":"C Banks","year":"2003","unstructured":"Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn\u2019s disease. J Pathol. 2003;199(1):28\u201335. https:\/\/doi.org\/10.1002\/path.1245.","journal-title":"J Pathol"},{"key":"2390_CR72","doi-asserted-by":"publisher","first-page":"972383","DOI":"10.3389\/fonc.2022.972383","volume":"12","author":"J Qiu","year":"2022","unstructured":"Qiu J, Xu L, Zeng X, Wu H, Liang F, Lv Q, et al. CCL5 mediates breast cancer metastasis and prognosis through CCR5\/Treg cells. Front Oncol. 2022;12:972383. https:\/\/doi.org\/10.3389\/fonc.2022.972383.","journal-title":"Front Oncol"},{"key":"2390_CR73","doi-asserted-by":"publisher","first-page":"30802","DOI":"10.1038\/srep30802","volume":"6","author":"A Mencarelli","year":"2016","unstructured":"Mencarelli A, Cipriani S, Francisci D, Santucci L, Baldelli F, Distrutti E, et al. Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis. Sci Rep. 2016;6:30802. https:\/\/doi.org\/10.1038\/srep30802.","journal-title":"Sci Rep"},{"key":"2390_CR74","doi-asserted-by":"publisher","first-page":"e43653","DOI":"10.7554\/elife.43653","volume":"8","author":"A Walens","year":"2019","unstructured":"Walens A, DiMarco AV, Lupo R, Kroger BR, Damrauer JS, Alvarez JV. CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors. Elife. 2019;8:e43653. https:\/\/doi.org\/10.7554\/elife.43653.","journal-title":"Elife"},{"issue":"4","key":"2390_CR75","doi-asserted-by":"publisher","first-page":"e23660","DOI":"10.4161\/onci.23660","volume":"2","author":"M Velasco-Vel\u00e1zquez","year":"2013","unstructured":"Velasco-Vel\u00e1zquez M, Pestell RG. The CCL5\/CCR5 axis promotes metastasis in basal breast cancer. Oncoimmunology. 2013;2(4):e23660. https:\/\/doi.org\/10.4161\/onci.23660.","journal-title":"Oncoimmunology"},{"issue":"7","key":"2390_CR76","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3390\/cancers12071765","volume":"12","author":"D Aldinucci","year":"2020","unstructured":"Aldinucci D, Borghese C, Casagrande N. The CCL5\/CCR5 axis in cancer progression. Cancers (Basel). 2020;12(7):1765. https:\/\/doi.org\/10.3390\/cancers12071765.","journal-title":"Cancers (Basel)"},{"issue":"18","key":"2390_CR77","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3390\/cells12182237","volume":"12","author":"R Hamid","year":"2023","unstructured":"Hamid R, Alaziz M, Mahal AS, Ashton AW, Halama N, Jaeger D, et al. The role and therapeutic targeting of CCR5 in breast cancer. Cells. 2023;12(18):2237. https:\/\/doi.org\/10.3390\/cells12182237.","journal-title":"Cells"},{"issue":"1","key":"2390_CR78","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1189\/jlb.1009671","volume":"88","author":"Q Zhao","year":"2010","unstructured":"Zhao Q. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J Leukoc Biol. 2010;88(1):41\u201355. https:\/\/doi.org\/10.1189\/jlb.1009671.","journal-title":"J Leukoc Biol"},{"key":"2390_CR79","doi-asserted-by":"publisher","first-page":"650453","DOI":"10.3389\/fonc.2021.650453","volume":"11","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zheng X, Zheng Y, Chen Y, Fei W, Wang F, et al. Extracellular matrix: emerging roles and potential therapeutic targets for breast cancer. Front Oncol. 2021;11:650453. https:\/\/doi.org\/10.3389\/fonc.2021.650453.","journal-title":"Front Oncol"},{"key":"2390_CR80","doi-asserted-by":"publisher","first-page":"859581","DOI":"10.3389\/fimmu.2022.859581","volume":"13","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Tian Q, Gao H, Zhu L, Zhang Y, Zhang C, et al. Immunity and extracellular matrix characteristics of breast cancer subtypes based on identification by T helper cells profiling. Front Immunol. 2022;13:859581. https:\/\/doi.org\/10.3389\/fimmu.2022.859581.","journal-title":"Front Immunol"},{"issue":"7","key":"2390_CR81","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/2159-8290.cd-12-0536","volume":"3","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Shin SJ, Liu D, Ivanova E, Foerster F, Ying H, et al. ZNF365 promotes stability of fragile sites and telomeres. Cancer Discov. 2013;3(7):798\u2013811. https:\/\/doi.org\/10.1158\/2159-8290.cd-12-0536.","journal-title":"Cancer Discov"},{"issue":"3","key":"2390_CR82","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/ng.760","volume":"43","author":"S Lindstr\u00f6m","year":"2011","unstructured":"Lindstr\u00f6m S, Vachon CM, Li J, Varghese J, Thompson D, Warren R, et al. Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet. 2011;43(3):185\u20137. https:\/\/doi.org\/10.1038\/ng.760.","journal-title":"Nat Genet"},{"issue":"8","key":"2390_CR83","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/gut.2010.227256","volume":"60","author":"T Haritunians","year":"2011","unstructured":"Haritunians T, Jones MR, McGovern DP, Shih DQ, Barrett RJ, Derkowski C, et al. Variants in ZNF365 isoform D are associated with Crohn\u2019s disease. Gut. 2011;60(8):1060\u20137. https:\/\/doi.org\/10.1136\/gut.2010.227256.","journal-title":"Gut"},{"issue":"5","key":"2390_CR84","first-page":"1803","volume":"11","author":"VJ Lazaro-Camp","year":"2021","unstructured":"Lazaro-Camp VJ, Salari K, Meng X, Yang S. SETDB1 in cancer: overexpression and its therapeutic implications. Am J Cancer Res. 2021;11(5):1803\u201327.","journal-title":"Am J Cancer Res"},{"issue":"8","key":"2390_CR85","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3390\/cancers11081143","volume":"11","author":"J Batham","year":"2019","unstructured":"Batham J, Lim PS, Rao S. SETDB-1: A potential epigenetic regulator in breast cancer metastasis. Cancers (Basel). 2019;11(8):1143. https:\/\/doi.org\/10.3390\/cancers11081143.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2390_CR86","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/path.5126","volume":"246","author":"J-F Xiao","year":"2018","unstructured":"Xiao J-F, Sun Q-Y, Ding L-W, Chien W, Liu X-Y, Mayakonda A, et al. The c-MYC-BMI1 axis is essential for SETDB1-mediated breast tumourigenesis. J Pathol. 2018;246(1):89\u2013102. https:\/\/doi.org\/10.1002\/path.5126.","journal-title":"J Pathol"},{"issue":"2","key":"2390_CR87","doi-asserted-by":"publisher","first-page":"139","DOI":"10.5483\/bmbrep.2019.52.2.235","volume":"52","author":"TY Ryu","year":"2019","unstructured":"Ryu TY, Kim K, Kim SK, Oh JH, Min JK, Jung CR, et al. SETDB1 regulates SMAD7 expression for breast cancer metastasis. BMB Rep. 2019;52(2):139\u201344. https:\/\/doi.org\/10.5483\/bmbrep.2019.52.2.235.","journal-title":"BMB Rep"},{"issue":"3","key":"2390_CR88","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/gutjnl-2020-321339","volume":"70","author":"L Ju\u017eni\u0107","year":"2021","unstructured":"Ju\u017eni\u0107 L, Peuker K, Strigli A, Brosch M, Herrmann A, H\u00e4sler R, et al. SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation. Gut. 2021;70(3):485\u201398. https:\/\/doi.org\/10.1136\/gutjnl-2020-321339.","journal-title":"Gut"},{"key":"2390_CR89","doi-asserted-by":"publisher","first-page":"215926","DOI":"10.1016\/j.canlet.2022.215926","volume":"550","author":"M Luo","year":"2022","unstructured":"Luo M, Li J, Yang Q, Xu S, Zhang K, Chen J, et al. N4BP3 promotes breast cancer metastasis via NEDD4-mediated E-cadherin ubiquitination and degradation. Cancer Lett. 2022;550:215926. https:\/\/doi.org\/10.1016\/j.canlet.2022.215926.","journal-title":"Cancer Lett"},{"issue":"1","key":"2390_CR90","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41420-024-02213-x","volume":"10","author":"W Jiang","year":"2024","unstructured":"Jiang W, Zhao Y, Han M, Xu J, Chen K, Liang Y, et al. N4BP3 facilitates NOD2-MAPK\/NF-\u03baB pathway in inflammatory bowel disease through mediating K63-linked RIPK2 ubiquitination. Cell Death Discov. 2024;10(1):440. https:\/\/doi.org\/10.1038\/s41420-024-02213-x.","journal-title":"Cell Death Discov"},{"key":"2390_CR91","doi-asserted-by":"publisher","first-page":"7167","DOI":"10.2147\/jir.s518155","volume":"18","author":"W Jiang","year":"2025","unstructured":"Jiang W, Yin J, Han M, He W, Zhao Y, Hu J, et al. N4BP3 activates TLR4-NF-\u03baB pathway in inflammatory bowel disease by promoting K48-linked I\u03baB\u03b1 ubiquitination. J Inflamm Res. 2025;18:7167\u201381. https:\/\/doi.org\/10.2147\/jir.s518155.","journal-title":"J Inflamm Res"},{"issue":"2","key":"2390_CR92","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cell.2021.12.024","volume":"185","author":"N Rana","year":"2022","unstructured":"Rana N, Privitera G, Kondolf HC, Bulek K, Lechuga S, De Salvo C, et al. GSDMB is increased in IBD and regulates epithelial restitution\/repair independent of pyroptosis. Cell. 2022;185(2):283\u2013e29817. https:\/\/doi.org\/10.1016\/j.cell.2021.12.024.","journal-title":"Cell"},{"key":"2390_CR93","doi-asserted-by":"publisher","first-page":"834805","DOI":"10.1155\/2015\/834805","volume":"2015","author":"J S\u00f6derman","year":"2015","unstructured":"S\u00f6derman J, Berglind L, Almer S. Gene expression-genotype analysis implicates GSDMA, GSDMB, and LRRC3C as contributors to inflammatory bowel disease susceptibility. Biomed Res Int. 2015;2015:834805. https:\/\/doi.org\/10.1155\/2015\/834805.","journal-title":"Biomed Res Int"},{"issue":"7","key":"2390_CR94","doi-asserted-by":"publisher","first-page":"E1128","DOI":"10.1073\/pnas.1616783114","volume":"114","author":"KL Chao","year":"2017","unstructured":"Chao KL, Kulakova L, Herzberg O. Gene polymorphism linked to increased asthma and IBD risk alters gasdermin-B structure, a sulfatide and phosphoinositide binding protein. Proc Natl Acad Sci U S A. 2017;114(7):E1128\u201337. https:\/\/doi.org\/10.1073\/pnas.1616783114.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2390_CR95","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13046-022-02497-w","volume":"41","author":"M G\u00e1mez-Chiachio","year":"2022","unstructured":"G\u00e1mez-Chiachio M, Molina-Crespo \u00c1, Ramos-Nebot C, Martinez-Val J, Martinez L, Gassner K, et al. Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation. J Exp Clin Cancer Res. 2022;41(1):285. https:\/\/doi.org\/10.1186\/s13046-022-02497-w.","journal-title":"J Exp Clin Cancer Res"},{"issue":"15","key":"2390_CR96","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1158\/1078-0432.ccr-18-2381","volume":"25","author":"\u00c1 Molina-Crespo","year":"2019","unstructured":"Molina-Crespo \u00c1, Cadete A, Sarrio D, G\u00e1mez-Chiachio M, Martinez L, Chao K, et al. Intracellular delivery of an antibody targeting gasdermin-B reduces HER2 breast cancer aggressiveness. Clin Cancer Res. 2019;25(15):4846\u201358. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-2381.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2390_CR97","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/s41418-023-01143-y","volume":"30","author":"SS Oltra","year":"2023","unstructured":"Oltra SS, Colomo S, Sin L, P\u00e9rez-L\u00f3pez M, L\u00e1zaro S, Molina-Crespo A, et al. Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells. Cell Death Differ. 2023;30(5):1366\u201381. https:\/\/doi.org\/10.1038\/s41418-023-01143-y.","journal-title":"Cell Death Differ"},{"issue":"82","key":"2390_CR98","doi-asserted-by":"publisher","first-page":"eadg3196","DOI":"10.1126\/sciimmunol.adg3196","volume":"8","author":"Q Kong","year":"2023","unstructured":"Kong Q, Xia S, Pan X, Ye K, Li Z, Li H, et al. Alternative splicing of GSDMB modulates killer lymphocyte-triggered pyroptosis. Sci Immunol. 2023;8(82):eadg3196. https:\/\/doi.org\/10.1126\/sciimmunol.adg3196.","journal-title":"Sci Immunol"},{"key":"2390_CR99","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1007\/s10620-023-08122-w","volume":"68","author":"KA Dunleavy","year":"2023","unstructured":"Dunleavy KA, Raffals LE, Camilleri M. Intestinal barrier dysfunction in inflammatory bowel disease: underpinning pathogenesis and therapeutics. Dig Dis Sci. 2023;68:4306\u201320. https:\/\/doi.org\/10.1007\/s10620-023-08122-w.","journal-title":"Dig Dis Sci"},{"issue":"7","key":"2390_CR100","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/ijms23073464","volume":"23","author":"PT Santana","year":"2022","unstructured":"Santana PT, Rosas SLB, Ribeiro BE, Marinho Y, de Souza HSP. Dysbiosis in inflammatory bowel disease: pathogenic role and potential therapeutic targets. Int J Mol Sci. 2022;23(7):3464. https:\/\/doi.org\/10.3390\/ijms23073464.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"2390_CR101","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.3390\/nu15204466","volume":"15","author":"Y Shin","year":"2023","unstructured":"Shin Y, Han S, Kwon J, Ju S, Choi TG, Kang I, et al. Roles of short-chain fatty acids in inflammatory bowel disease. Nutrients. 2023;15(20):4466. https:\/\/doi.org\/10.3390\/nu15204466.","journal-title":"Nutrients"},{"issue":"4","key":"2390_CR102","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/immuno4040026","volume":"4","author":"HF Hetta","year":"2024","unstructured":"Hetta HF, Ramadan YN, Alharbi AA, Alsharef S, Alkindy TT, Alkhamali A, et al. Gut microbiome as a target of intervention in inflammatory bowel disease pathogenesis and therapy. Immuno. 2024;4(4):400\u201325. https:\/\/doi.org\/10.3390\/immuno4040026.","journal-title":"Immuno"},{"key":"2390_CR103","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13027-025-00722-7","volume":"21","author":"YN Ramadan","year":"2026","unstructured":"Ramadan YN, Alatawi MN, Albalawi AS, Hetta HF. Bacterial contributions to cancer development: mechanisms, dysbiosis, and cross-cancer associations. Infect Agents Cancer. 2026;21:11. https:\/\/doi.org\/10.1186\/s13027-025-00722-7.","journal-title":"Infect Agents Cancer"},{"issue":"18","key":"2390_CR104","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1016\/j.cell.2022.07.016","volume":"185","author":"J Suez","year":"2022","unstructured":"Suez J, Cohen Y, Valdes-Mas R, Mor U, Dori-Bachash M, Federici S, et al. Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance. Cell. 2022;185(18):3307\u2013e332819. https:\/\/doi.org\/10.1016\/j.cell.2022.07.016.","journal-title":"Cell"},{"key":"2390_CR105","doi-asserted-by":"publisher","first-page":"112237","DOI":"10.1016\/j.nut.2023.112237","volume":"117","author":"E Gauthier","year":"2024","unstructured":"Gauthier E, Milagro FI, Navas-Carretero S. Effect of low-and non-calorie sweeteners on the gut microbiota: a review of clinical trials and cross-sectional studies. Nutrition. 2024;117:112237. https:\/\/doi.org\/10.1016\/j.nut.2023.112237.","journal-title":"Nutrition"},{"issue":"4","key":"2390_CR106","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/diseases13040115","volume":"13","author":"HF Hetta","year":"2025","unstructured":"Hetta HF, Sirag N, Elfadil H, Salama A, Aljadrawi SF, Alfaifi AJ, et al. Artificial sweeteners: a double-edged sword for gut microbiome. Diseases. 2025;13(4):115. https:\/\/doi.org\/10.3390\/diseases13040115.","journal-title":"Diseases"},{"key":"2390_CR107","doi-asserted-by":"publisher","first-page":"631552","DOI":"10.3389\/fcell.2021.631552","volume":"9","author":"Y Sui","year":"2021","unstructured":"Sui Y, Wu J, Chen J. The role of gut microbial \u03b2-Glucuronidase in Estrogen reactivation and breast cancer. Front Cell Dev Biol. 2021;9:631552. https:\/\/doi.org\/10.3389\/fcell.2021.631552.","journal-title":"Front Cell Dev Biol"},{"issue":"13","key":"2390_CR108","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.3390\/ijms20133175","volume":"20","author":"D Jacenik","year":"2019","unstructured":"Jacenik D, Cygankiewicz AI, Mokrowiecka A, Malecka-Panas E, Fichna J, Krajewska WM. Sex- and age-related estrogen signaling alteration in inflammatory bowel diseases: modulatory role of estrogen receptors. Int J Mol Sci. 2019;20(13):3175. https:\/\/doi.org\/10.3390\/ijms20133175.","journal-title":"Int J Mol Sci"},{"issue":"30","key":"2390_CR109","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.3748\/wjg.v25.i30.4092","volume":"25","author":"D Jacenik","year":"2019","unstructured":"Jacenik D, Beswick EJ, Krajewska WM, Prossnitz ER. G protein-coupled estrogen receptor in colon function, immune regulation and carcinogenesis. World J Gastroenterol. 2019;25(30):4092\u2013104. https:\/\/doi.org\/10.3748\/wjg.v25.i30.4092.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2390_CR110","doi-asserted-by":"publisher","first-page":"6749","DOI":"10.1038\/s41598-019-43233-3","volume":"9","author":"D Jacenik","year":"2019","unstructured":"Jacenik D, Zieli\u0144ska M, Mokrowiecka A, Michlewska S, Ma\u0142ecka-Panas E, Kordek R, et al. G protein-coupled estrogen receptor mediates anti-inflammatory action in Crohn\u2019s disease. Sci Rep. 2019;9(1):6749. https:\/\/doi.org\/10.1038\/s41598-019-43233-3.","journal-title":"Sci Rep"},{"issue":"12","key":"2390_CR111","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nrendo.2011.122","volume":"7","author":"ER Prossnitz","year":"2011","unstructured":"Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol. 2011;7(12):715\u201326. https:\/\/doi.org\/10.1038\/nrendo.2011.122.","journal-title":"Nat Rev Endocrinol"},{"key":"2390_CR112","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jsbmb.2017.02.019","volume":"176","author":"R Lappano","year":"2018","unstructured":"Lappano R, Maggiolini M. GPER is involved in the functional liaison between breast tumor cells and cancer-associated fibroblasts (CAFs). J Steroid Biochem Mol Biol. 2018;176:49\u201356. https:\/\/doi.org\/10.1016\/j.jsbmb.2017.02.019.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2390_CR113","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.mce.2016.04.011","volume":"429","author":"D Jacenik","year":"2016","unstructured":"Jacenik D, Cygankiewicz AI, Krajewska WM. The G protein-coupled estrogen receptor as a modulator of neoplastic transformation. Mol Cell Endocrinol. 2016;429:10\u20138. https:\/\/doi.org\/10.1016\/j.mce.2016.04.011.","journal-title":"Mol Cell Endocrinol"},{"key":"2390_CR114","doi-asserted-by":"publisher","first-page":"24354","DOI":"10.1038\/srep24354","volume":"6","author":"P De Marco","year":"2016","unstructured":"De Marco P, Lappano R, De Francesco EM, Cirillo F, Pupo M, Avino S, et al. GPER signalling in both cancer-associated fibroblasts and breast cancer cells mediates a feedforward IL1\u03b2\/IL1R1 response. Sci Rep. 2016;6:24354. https:\/\/doi.org\/10.1038\/srep24354.","journal-title":"Sci Rep"},{"issue":"1","key":"2390_CR115","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/jgh.16795","volume":"40","author":"T Zhang","year":"2025","unstructured":"Zhang T, Li X, Li J, Sun F, Duan L. Gut microbiome-targeted therapies as adjuvant treatments in inflammatory bowel diseases: a systematic review and network meta-analysis. J Gastroenterol Hepatol. 2025;40(1):78\u201388. https:\/\/doi.org\/10.1111\/jgh.16795.","journal-title":"J Gastroenterol Hepatol"},{"key":"2390_CR116","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41575-021-00440-6","volume":"18","author":"S Salminen","year":"2021","unstructured":"Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, et al. The international scientific association of probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18:649\u201367. https:\/\/doi.org\/10.1038\/s41575-021-00440-6.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"2390_CR117","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/biology12020280","volume":"12","author":"MS Thu","year":"2023","unstructured":"Thu MS, Ondee T, Nopsopon T, Farzana IAK, Fothergill JL, Hirankarn N, et al. Effect of probiotics in breast cancer: a systematic review and meta-analysis. Biology (Basel). 2023;12(2):280. https:\/\/doi.org\/10.3390\/biology12020280.","journal-title":"Biology (Basel)"},{"issue":"3","key":"2390_CR118","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","volume":"166","author":"AF Peery","year":"2024","unstructured":"Peery AF, Kelly CR, Kao D, Vaughn BP, Lebwohl B, Singh S, et al. AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases. Gastroenterology. 2024;166(3):409\u201334. https:\/\/doi.org\/10.1053\/j.gastro.2024.01.008.","journal-title":"Gastroenterology"},{"issue":"4","key":"2390_CR119","doi-asserted-by":"publisher","first-page":"CD012774","DOI":"10.1002\/14651858.CD012774.pub3","volume":"4","author":"A Imdad","year":"2023","unstructured":"Imdad A, Pandit NG, Zaman M, Minkoff NZ, Tanner-Smith EE, Gomez-Duarte OG, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2023;4(4):CD012774. https:\/\/doi.org\/10.1002\/14651858.CD012774.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"2390_CR120","doi-asserted-by":"publisher","first-page":"101754","DOI":"10.1016\/j.smim.2023.101754","volume":"67","author":"R Jamal","year":"2023","unstructured":"Jamal R, Messaoudene M, de Figuieredo M, Routy B. Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology. Semin Immunol. 2023;67:101754. https:\/\/doi.org\/10.1016\/j.smim.2023.101754.","journal-title":"Semin Immunol"},{"key":"2390_CR121","doi-asserted-by":"publisher","first-page":"1398652","DOI":"10.3389\/fimmu.2024.1398652","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, Li XM, Duan HY, Yang KD, Ye JF. Advances and optimization strategies in bacteriophage therapy for treating inflammatory bowel disease. Front Immunol. 2024;15:1398652. https:\/\/doi.org\/10.3389\/fimmu.2024.1398652.","journal-title":"Front Immunol"},{"key":"2390_CR122","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s43094-025-00825-3","volume":"11","author":"YN Ramadan","year":"2025","unstructured":"Ramadan YN, Rashed ZI, Ahmed R, Salem HA, Alshareef H, Ahmad-Abakur EH, et al. Bacteriophages: unlocking a new frontier in breast cancer management by defeating oncogenic bacteria. Future J Pharm Sci. 2025;11:74. https:\/\/doi.org\/10.1186\/s43094-025-00825-3.","journal-title":"Future J Pharm Sci"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02390-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02390-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02390-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:27:22Z","timestamp":1791826042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-026-02390-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":122,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2390"],"URL":"https:\/\/doi.org\/10.1007\/s00011-026-02390-8","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During preparation of the revised manuscript, the authors used ChatGPT solely for English-language polishing. The authors reviewed and edited the text and take full responsibility for the content of the manuscript.","order":4,"name":"Ethics","label":"Use of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"235"}}